Expansion through acquisitions Metagenics recently acquired Symprove, a UK probiotic brand, signaling a strategy to broaden its digestive health portfolio and cross-border market access. This creates cross-sell opportunities with Symprove customers and opens dialogue with European healthcare providers seeking integrated nutraceutical solutions.

Clinical partnerships A long-standing collaboration with HormoneSynergy spanning over 25 years suggests strong alignment with clinic-based, personalized medicine. Leverage this to propose joint program development, education, and co-branded nutrigenomic solutions to clinics focused on hormone health and lifestyle medicine.

High growth leadership New CEO Patrick Sly appointed in 2025 alongside a track record of rapid growth provides a signal of strategic investment and expansion. Position sales outreach around scalable, evidence-first product lines and turnkey programs designed for health systems and specialty clinics seeking rapid onboarding.

Innovative product line HerWellness introduced in 2025 targets hormone balance across a woman’s lifecycle, reflecting consumer-focused, evidence-backed offerings. Market opportunities exist in OB/GYN, integrative care, fertility clinics, and wellness practices that emphasize personalized nutrition.

Strong market positioning Metagenics operates as a top doctor-recommended professional supplement brand with a substantial revenue range and broad professional presence. Upsell and channel opportunities include partnerships with clinics, chiropractic networks, and wellness centers that serve nutrigenomics-informed care and lifestyle medicine.